GlassScriptPhysician profile
Renata Estes
NPI 1891031076
$3,451.06
in general payments reported to CMS, 2019-2025
33 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $810 · 2022: $892 · 2023: $775 · 2024: $787 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.62 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $545.55 | 2021-2024 | |
| Evofem Biosciences, INC. | $322.50 | 2021-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $312.56 | 2021-2024 | |
| Exeltis, USA INC. | $277.83 | 2021-2025 | Slynd |
| Novo Nordisk INC | $248.13 | 2021-2023 | Wegovy |
| Astellas Pharma US INC | $231.43 | 2023-2025 | Veozah |
| Coloplast Corp | $195.44 | 2023-2025 | Speedicath |
| Therapeuticsmd, INC. | $125.51 | 2021-2022 | |
| Pfizer INC. | $93.82 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $90.08 | 2023-2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $88.64 | 2022-2024 | Belsomra, Gardasil, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $85.69 | 2023-2024 | Quviviq |
| Avion Pharmaceuticals | $77.97 | 2021-2022 | |
| Agile Therapeutics, INC. | $72.54 | 2021-2024 | Twirla |
| Eisai INC. | $70.37 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $56.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.29 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.15 | 2022 | |
| Coopersurgical, INC. | $50.68 | 2022-2024 | Paragard T 380a |
| Millicent US INC | $46.16 | 2024-2025 | Intrarosa, Femring |
| Myovant Sciences INC. | $42.12 | 2022 | |
| Exact Sciences Corporation | $39.92 | 2024-2025 | Cologuard Collection Kit |
| Lupin INC. | $37.90 | 2021 | |
| Ascend Therapeutics US, LLC | $33.65 | 2022 | |
| Vivus LLC | $33.56 | 2021 | |
| Hologic Sales and Service, LLC | $29.02 | 2024 | Aptima |
| Urovant Sciences INC | $28.42 | 2021-2022 | |
| Mimedx Group, INC. | $23.82 | 2024 | |
| Allergan, INC. | $20.53 | 2021 | |
| Avation Medical, INC. | $17.33 | 2024 | Vivally |
| Axonics, INC. | $15.22 | 2021 | |
| Organon LLC | $13.92 | 2024 | |
| Currax Pharmaceuticals LLC | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renata Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.